Lori J. Wirth, MD, Massachusetts General Hospital

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Shared insight on the optimal use of RET inhibitor therapy in select patients with RET-rearranged radioiodine-refractory differentiated thyroid cancer.

Centering discussion on the final clinical scenario of RR DTC, Francis Worden, MD, highlights the management of a patient with an identified RET rearrangement.

Expert panelists provide comprehensive insight to the utilization of second-line therapy for patients with RR DTC, covering formulation, dosing, and adverse event management.

A broad view of clinical data behind use of cabozantinib therapy in the second-line setting of radioiodine-refractory differentiated thyroid cancer.

Moving on to a new clinical scenario, Lori Wirth, MD, reviews the second-line management of a patient who progresses on frontline systemic therapy.

Before closing out their discussion on the frontline treatment setting of RR DTC, panelists highlight dose reductions and planned treatment holidays to mitigate adverse events.

Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.

Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.

A brief review of when it is appropriate to initiate systemic therapy in patients with differentiated thyroid cancer as opposed to continuing active surveillance.

Key opinion leaders in differentiated thyroid cancer take a moment to define radioiodine refractory disease and consider its implications in establishing a treatment pathway.

Comprehensive insight on best practices in dose adjustment and adverse event management in patients receiving systemic therapy for RR DTC.

Expert Marcia Brose, MD, PhD, reviews a patient case of radioiodine-refractory differentiated thyroid cancer (RR DTC) managed with frontline lenvatinib therapy.

Shared insight on best practices in diagnosing patients with differentiated thyroid cancer with a focus on histologic and molecular subtypes.

Opening discussion on the advent of differentiated thyroid cancer (DTC) and management, moderator Lori J. Wirth, MD, provides and overview of prevalence, subtypes, and prognosis.

Experts in oncology discuss future directions in biomarker-driven therapy.

Dr Mark Socinski describes the design and findings of the CRESTONE trial.

Dr Jyoti Patel presents data from the ARROW clinical trial.

Lori Wirth, MD, reviews the phase 1/2 LIBRETTO-001 trial.

Expert oncologists discuss RET-driven therapy for select solid tumors.

Experts discuss their personal experiences when treating patients with NRTK fusions and solid tumors.

Jonathan Trent, MD, PhD, describes the safety and efficacy data from clinical trials of larotrectinib in patients with NRTK fusion–positive solid tumors.

Benjamin Levy, MD, reviews the available treatment options for patients whose tumors harbor NRTK fusions.

Dr Lori Wirth describes the importance and implications of testing for NRTK fusions in patients with solid tumors.

Dr Mark Socinski and panel discuss the challenges and unmet meets of biomarker-driven therapy across solid tumor types.

Experts in oncology provide their insights on the use of companion diagnostics in the treatment of solid tumors. 

A panel of oncology experts in lung, thyroid, and sarcomatous tumors discuss the role and impact of pan-tumor biomarker testing.

Jyoti Patel, MD, FASCO, discusses the pros and cons of tissue versus blood for molecular testing of solid tumors.

Benjamin Levy, MD, and a multispecialty panel of experts discuss the importance of biomarker-directed therapy for appropriate solid tumors.